FOLD News and Press, Amicus Therapeutics Inc. From 01/11/21

Full-Year 2020 Galafold ® Revenue of ~$261M Exceeds Guidance Strengthened Galafold IP Portfolio Now Includes 24 Issued Patents Including 13 Patents through 2038 Pompe Phase 3 PROPEL Study Last Patient, Last Visit Complete with Data...

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference, being held virtually on Tuesday, January 12, 2021 at 8...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been nationally recognized as a Great Place...

CRANBURY, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serv...

Sigilon Therapeutics has filed proposed terms for its $101 million U.S. IPO. The firm is advancing programs to treat blood, lysosomal storage and other diseases. SGTX has produced a positive initial result with its first trial patient, has a strong collaboration relationship with ...

Amicus Therapeutics (FOLD) has initiated rolling marketing application to the FDA for AT-GAA for the treatment of late onset Pompe disease ((LOPD)), an inherited metabolic disorder caused by the buildup of glycogen in the body's cells due to mutations in the gene that codes for an e...

On Track for Completing the BLA Submission in 1H2021 All PPQ Drug Substance and Drug Product Activities for Man ufacturing Now Successfully Completed Data from Phase 3 Propel Study Expected 1Q2021 CRANBURY, N.J., Dec. 01, 2020 (G...

CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore ISI 3 rd Annual HealthCONx Conference being held virtually on Tuesday, December 1, 2...

Sigilon Therapeutics has filed to raise capital via an IPO. The firm is developing treatments for blood disorders and other diseases. SGTX has produced intriguing preclinical study results for its lead candidate for the treatment of Hemophilia A. For further details see: ...